SCHEMBL2270577

SCHEMBL2270577

CCCCCCCCCCCc1cccnc1C(=O)O.[Zn]

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.55
MAPT P10636 3/20 0.55
CYP1A2 P05177 1/20 0.55
BID P55957 3/20 0.52
MCL1 Q07820 3/20 0.52
PPARA Q07869 3/20 0.52
BCL2L1 Q07817 2/20 0.52
BAK1 Q16611 2/20 0.52
KAT8 Q9H7Z6 2/20 0.52
PPARG P37231 2/20 0.52
SAE1 Q9UBE0 2/20 0.52
EP300 Q09472 1/20 0.52
KAT2A Q92830 1/20 0.52
KAT2B Q92831 1/20 0.52
KAT5 Q92993 1/20 0.52
F7 P08709 3/20 0.46
F3 P13726 3/20 0.46
MMP2 P08253 2/20 0.46
ALOX15 P16050 2/20 0.46
ECE1 P42892 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24908480 0.98 KDM4E (0.57) KDM4EMAPTCYP1A2BIDMCL1
SCHEMBL9094733 0.98 KDM4E (0.57) KDM4EMAPTCYP1A2BIDMCL1
SCHEMBL29184951 0.98 KDM4E (0.57) KDM4EMAPTCYP1A2BIDMCL1
SCHEMBL5498415 0.97 KDM4E (0.58) KDM4EMAPTCYP1A2BIDMCL1
SCHEMBL9295028 0.92 KDM4E (0.60) KDM4EMAPTCYP1A2BIDMCL1
SCHEMBL22653038 0.85 KDM4E (0.64) KDM4EMAPTCYP1A2ALOX15ALDH1A1
SCHEMBL5922587 0.85 BID (0.46) KDM4EMAPTCYP1A2BIDMCL1
SCHEMBL14786046 0.85 BID (0.46) KDM4EMAPTCYP1A2BIDMCL1
SCHEMBL31500502 0.85 BID (0.46) KDM4EMAPTCYP1A2BIDMCL1
SCHEMBL18598998 0.84 BID (0.44) KDM4EMAPTCYP1A2BIDMCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8003688-B2 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract IMMUPHARM APS (DK) 2011-08-23 US disclosed
US-7671086-B2 Pharmaceutical compositions comprising flavonoids and menthol IMMUPHARM A/S (DK) 2010-03-02 US disclosed
US-20090227670-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING FLAVONOIDS AND MENTHOL IMMUPHARM A/S (DK) 2009-09-10 US disclosed
US-7585890-B2 Pharmaceutical compositions comprising flavonoids and menthol IMMUNPHARM A/S (DK) 2009-09-08 US disclosed
EP-2089422-A1 METHODS OF SEPARATING NUCLEIC ACIDS AND PROTEIN Natimmune A/S (DK) 2009-08-19 EP disclosed
WO-2008106979-A2 PHARMACEUTICAL COMPOSITIONS COMPRISING FLAVONOIDS AND XYLITOL IMMUPHARM A/S (DK) 2008-09-12 WO disclosed
CN-100411617-C Method of treating symptons of common cold allergic rhinitis and infections relating to the respiratory tract IMMUPHARM APS (DK) 2008-08-20 CN disclosed
WO-2008064686-A1 METHODS OF SEPARATING NUCLEIC ACIDS AND PROTEIN NATIMMUNE A/S (DK) 2008-06-05 WO disclosed
EP-1556021-B1 PHARMACEUTICAL COMPOSITIONS COMPRISING FLAVONOIDS AND MENTHOL IMMUPHARM AS (DK) 2007-12-19 EP disclosed
US-7166640-B2 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract IMMUPHARM APS (DK) 2007-01-23 US disclosed
US-20050245467-A1 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract IMMUPHARM APS (DK) 2005-11-03 US disclosed
EP-1556021-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING FLAVONOIDS AND MENTHOL Immupharm A/S (DK) 2005-07-27 EP disclosed
WO-2004037237-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING FLAVONOIDS AND MENTHOL IMMUPHARM A/S (DK) 2004-05-06 WO disclosed
US-20040053858-A1 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract IMMUPHARM APS (DK) 2004-03-18 US disclosed
CN-1466454-A Method for treating symptoms of common cold, allergic rhinitis and respiratory tract related infections ���·�ķ��˾ 2004-01-07 CN disclosed
EP-1307189-A2 METHOD OF TREATING SYMPTOMS OF COMMON COLD, ALLERGIC RHINITIS AND INFECTIONS RELATING TO THE RESPIRATORY TRACT Immupharm APS (DK) 2003-05-07 EP disclosed
WO-2002009699-A2 METHOD OF TREATING SYMPTOMS OF COMMON COLD, ALLERGIC RHINITIS AND INFECTIONS RELATING TO THE RESPIRATORY TRACT IMMUPHARM APS (DK) 2002-02-07 WO disclosed
EP-0433457-B1 ANTIPRURITIC COMPOSITION SHISEIDO CO LTD (JP) 1994-10-19 EP disclosed
US-5219847-A Antipruritic composition SHISEIDO COMPANY, LTD. (JP) 1993-06-15 US disclosed
EP-0433457-A1 ANTIPRURITIC COMPOSITION SHISEIDO COMPANY LIMITED (JP) 1991-06-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245467-A1 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract CMA1, CHIA, C1QBP KDM4E 4189/4885MAPT 2199/4885CYP1A2 310/4885
US-20040053858-A1 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract CMA1, CHIA, C1QBP KDM4E 4189/4885MAPT 2199/4885CYP1A2 310/4885
US-20090227670-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING FLAVONOIDS AND MENTHOL CHIA, MAVS, C1QBP KDM4E 430/4885MAPT 687/4885CYP1A2 99/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.